No Data
Chengdu HuaWei: Report of Chengdu HuaWei Electronics Technology Co., Ltd. for the third quarter of 2024
Chengdu HuaWei Electronics Technology Co., Ltd. Report for the Third Quarter of 2024
Chengdu Huaweimicro (688709.SH): The net income for the first three quarters was 87.9584 million yuan, a 54.98% year-on-year decrease.
On October 30, Gelonghui announced that Chengdu Huawei (688709.SH) achieved total operating revenue of 0.423 billion yuan in the first three quarters of 2024, a decrease of 32.78% year-on-year; the net income attributable to shareholders of the parent company was 87.9584 million yuan, a decrease of 54.98% year-on-year; the basic earnings per share was 0.14 yuan.
Chengdu Huawei (688709.SH): The company's overall R&D progress is currently normal.
Gelonghui October 16th | Chengdu Huawei (688709.SH) recently stated at the 2024 half-year performance briefing that the company's overall R&D progress is normal. From January to June 2024, R&D expenditure accounted for 26.25% of revenue. As of June 30, 2024, the company owned a total of 108 domestic invention patents, 5 overseas invention patents, 203 integrated circuit layout design rights, and 29 software copyrights. The company attaches great importance to the introduction and training of R&D talents. As of June 30, 2024, the company has a total of 388 R&D personnel, accounting for
Is Chengdu Sino-Microelectronics Tech. Co., Ltd.'s (SHSE:688709) Latest Stock Performance A Reflection Of Its Financial Health?
Chengdu Huawei (688709.SH): The company's human brain engineering related project is currently in the testing phase.
On October 9th, some investors asked Chengdu HuawWei (688709.SH) through the interactive platform: How is the progress of the newly added concept of human brain engineering by Chengdu HuawWei, and what breakthroughs will Chengdu HuawWei make in the field of human brain engineering technology in the future? Chengdu HuawWei (688709.SH) replied: The company's human brain engineering related project is currently in the testing phase, and in the future, it will mainly focus on breakthroughs in improving the accuracy of brain-computer interface signal acquisition. This matter does not have a significant impact on the company's production operation, please pay attention to the investment risk.
